Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088192 · ClinicalTrials.gov registry record · NA
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
A NA study, sponsored by Eyetech Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
NCT00088192 is a NA study that has completed, run by Eyetech Pharmaceuticals.
The verdict
NCT00088192, a NA study, has completed, sponsored by Eyetech Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor's other clinical studies with this drug for AMD, until such time as the patient's lesion is considered to have resolved or stabilized in the opinion of the treating ophthalmologist, or product becomes commercially available.
Interventions
- DRUG pegaptanib sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088192
The ClinicalTrials.gov registry entry for NCT00088192 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eyetech Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pegaptanib sodium is the first listed.
NCT00088192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088192 about?
NCT00088192 is a clinical study titled "Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)". To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor's other clinical studies with this drug for AMD, until such time as the patient's lesion is considered to have resolved or stabil...
What is the current status of trial NCT00088192?
This trial is currently completed. It is a NA study. The study started on 2004-07.
What interventions are being tested in trial NCT00088192?
The interventions under investigation include: pegaptanib sodium (DRUG).
Who is sponsoring clinical trial NCT00088192?
This trial is sponsored by Eyetech Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.